First longevity firm to list in Europe bets on 'major exit'
It could take years to develop a gene therapy to slow aging, but much less for big pharma to scoop up Genflow Biosciences
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: